ArcBest shorts retreat as options sentiment shifts

Options positioning tells a complementary but more nuanced story. The put/call ratio has dropped to 0.72, well below its 20-day average of 0.98, suggesting call demand has picked up relative to recent norms. But context matters: the PCR was running at 1.48 in mid-September, the 52-week high, meaning the market spent much of the past month loaded with downside protection. The current reading is a significant unwind of that defensiveness, not a full-throated bullish shift. The z-score of minus 0.70 captures this: options are now slightly more bullish than usual, but hardly euphoric.

The Street remains cautiously constructive, though targets have been drifting lower. Truist Securities trimmed its target this week to $160 from $165 while holding a Buy rating, a pattern repeated by Citigroup in early August (Buy, target cut to $171 from $178). The mean price target across analysts is $168, implying meaningful upside from the current price near $128, but the direction of recent moves is southward. UBS, sitting at Neutral, actually raised its target in early August to $154, while TD Cowen cut to $155 from $175 on a Hold. The overall picture is a Street that still sees recovery value but is trimming expectations. EPS momentum factor scores are strong, ranking in the 76th and 89th percentile on 30- and 90-day windows respectively, and the 12-month forward EPS growth rank hits the 91st percentile. Against that, the EV/EBIT factor ranks in just the 12th percentile, reflecting stretched enterprise value relative to operating earnings. The PE has compressed around 14.3x over 30 days, down about 2 points.

The fundamental debate between bulls and bears maps fairly cleanly onto near-term versus medium-term uncertainty. The bull case rests on Q1 results that beat estimates, LTL contract renewals at their strongest since late 2022, and an Asset-Light segment that swung to profitability with revenue per day up 24% year-on-year through late April. The bear case points to a weak demand and pricing environment that makes the company's margin recovery look slow, with fuel costs, union labor, and North American macro exposure all acting as potential headwinds. Out-year estimates may still face downward revisions if volume momentum stalls.

Insider activity over the past 90 days has been one-directional. Net selling totalled around $3.2 million across open-market transactions, with the Chief Innovation Officer and two board directors among the sellers in early August. None of the trades were disclosed under a 10b5-1 pre-arranged plan, which makes them marginally more informative as signals of insider sentiment, though the amounts are not large enough to read as a strong conviction statement. No buying has appeared in the register.

One standout from the alt-data layer: retail attention to ARCB has spiked sharply. The signal tracking Wikipedia views and ORTEX page traffic against its own 90-day history registered a z-score of nearly 4.0 as of late September, meaning retail interest is running far above normal. This is an attention metric, not a revenue or earnings indicator, but sustained spikes at this level often accompany periods of price volatility or renewed narrative interest.

With Q3 results due November 4, the next four weeks will test whether the short-covering trend continues as the print approaches, or whether bears rebuild ahead of what recent earnings history suggests can be a volatile reporting event: the two most recent quarterly releases both produced one-day declines of around 3% to 5%.